velpatasvir
Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
Chemical data
- Formula
- C49H54N8O8
- Molecular weight
- 883 g/mol
- IUPAC name
- methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
via PubChem
Research
800 papers- Velpatasvir.2006
- Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C.Australian prescriber · 2019
- Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.Medicine · 2022
- Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients.Expert review of gastroenterology & hepatology · 2021
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Article
7 sectionsContents
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- See also
- References
{{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate | image = Velpatasvir.svg | image_class = skin-invert-image | width = 275
| tradename = Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir) | pregnancy_AU = | pregnancy_US = | pregnancy_category = | licence_EU = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral (tablets)